2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride
C25H30Cl4N4O3 — CID 146058182
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride
2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride (PubChem CID 146058182) has the molecular formula C25H30Cl4N4O3 and a molecular weight of 576.35 g/mol. Its IUPAC name is 2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride.
Molecular Properties
| Compound Name | 2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride |
|---|---|
| PubChem CID | 146058182 |
| Molecular Formula | C25H30Cl4N4O3 |
| Molecular Weight | 576.35 g/mol |
| Exact Mass | 574.11 |
| IUPAC Name | 2-[4-(3-chlorophenyl)piperazin-1-yl]-6-(pentanoylamino)quinoline-4-carboxylic acid;trihydrochloride |
| SMILES | CCCCC(=O)Nc1ccc2nc(N3CCN(c4cccc(Cl)c4)CC3)cc(C(=O)O)c2c1.Cl.Cl.Cl |
| InChI | InChI=1S/C25H27ClN4O3.3ClH/c1-2-3-7-24(31)27-18-8-9-22-20(15-18)21(25(32)33)16-23(28-22)30-12-10-29(11-13-30)19-6-4-5-17(26)14-19;;;/h4-6,8-9,14-16H,2-3,7,10-13H2,1H3,(H,27,31)(H,32,33);3*1H |
| InChIKey | CUAIIPMORXPKLA-UHFFFAOYSA-N |
| XLogP | 6.31 |
| TPSA | 85.77 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 576.35 |
| LogP ≤ 5 | 6.31 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146058182 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.